{"id":85406,"date":"2024-10-01T11:53:06","date_gmt":"2024-10-01T11:53:06","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/briacell-reports-100-resolution-of-brain-metastasis-in-breast-cancer-patient-with-eye-bulging-tumor\/"},"modified":"2024-10-01T11:53:06","modified_gmt":"2024-10-01T11:53:06","slug":"briacell-reports-100-resolution-of-brain-metastasis-in-breast-cancer-patient-with-eye-bulging-tumor","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/briacell-reports-100-resolution-of-brain-metastasis-in-breast-cancer-patient-with-eye-bulging-tumor\/","title":{"rendered":"BriaCell Reports 100% Resolution of Brain Metastasis in Breast Cancer Patient with \u201cEye-Bulging\u201d Tumor"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<ul type=\"disc\">\n<li style=\"text-align:justify;\"><strong><em>Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with \u201cEye-Bulging\u201d metastatic breast cancer<\/em><\/strong><\/li>\n<li style=\"text-align:justify;\"><strong><em>Heavily pre-treated patient had failed 8 prior regimens including antibody-drug<\/em><\/strong><strong><em> conjugate<\/em><\/strong> (<strong><em>ADC) therapy and continues to receive BriaCell treatment<\/em><\/strong><\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, Oct.  01, 2024  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report dramatic anti-tumor response including complete resolution of temporal lobe breast cancer metastasis in a patient treated in the Phase 2 study of BriaCell\u2019s Bria-IMT\u2122 plus an immune checkpoint inhibitor regimen. The patient demonstrated an initial partial response at 2 months in the brain lesion with no detectable disease following 8 and 11 months of treatment.<\/p>\n<p align=\"justify\">The heavily pre-treated patient who had failed 8 prior regimens including ADC therapy, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eZaA1J1B60wk9VnJtg61vnP3b3zNf1xAC7c5kB-7idfY0uZ86liM94EFUQ7BqzW9acNUNREQ5fxpbK8SXeffcvQUJH8zbLbMBJrcJX-aiZ-g5E_87bQckP8VFQlXnoLzXtbzUKjPFgwY8yB4av-4uw4jeNK4LWas1yLZd1GSIgYRFHrygUAr1PvR4y6t71rF_sP8sBncxzBrDT7AZ-XNC8IuzIBIxKSpFbE1Lgcj09Kct8GzGawooafh__xsF1ZK\" rel=\"nofollow noopener\" target=\"_blank\" title=\"previously demonstrated significant reduction of her \u201cEye-Bulging\u201d orbital tumor\">previously demonstrated significant reduction of her \u201cEye-Bulging\u201d orbital tumor<\/a> and continues treatment with the Bria-IMT\u2122 regimen. She has completed 17 cycles of treatment and has been on BriaCell\u2019s Phase 2 study for 12 months. Also noteworthy is a sustained drop in her tumor markers, confirming the imaging results of marked tumor reduction.<\/p>\n<p align=\"justify\"><strong>Figure 1: Bria-IMT\u2122 regimen resulted in 100% resolution of tumor in the right temporal lobe region of the brain<\/strong><\/p>\n<p align=\"justify\"><strong><br \/><\/strong><\/p>\n<p align=\"justify\">As shown in Figure 1, the right temporal lobe lesion is no longer detectable on the images taken at 8 months and 11 months on the Bria-IMT\u2122 combination regimen. The orbital lesion has continued to shrink markedly (Figure 2). In addition, her tumor markers (blood tests that correlate with the amount of tumor in the body) remain markedly decreased from her pre-treatment levels.<\/p>\n<p align=\"justify\"><strong>Figure 2: Bria-IMT\u2122 regimen resulted in near complete resolution of breast cancer tumor in the right orbit (behind the eye)<\/strong><\/p>\n<p align=\"center\"><img fetchpriority=\"high\" decoding=\"async\" alt=\"Figure 2\" height=\"397\" name=\"GNW_RichHtml_External_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/eea9560e-c63a-4001-a5b7-6a07caf3c91b\/f2-2024-09-30-210728.jpg\" width=\"600\"\/><\/p>\n<p align=\"justify\">\u201cBria-IMT\u2122\u2019s potential therapeutic impact is unprecedented in metastatic breast cancer (MBC) in a brain metastasis setting. Our clinical findings, demonstrating significant tumor shrinkage in metastatic brain legions, may transform the way we treat MBC patients with brain metastasis, and offers hope to cancer patients and their families fighting this devastating disease,\u201d stated Dr. William V. Williams, BriaCell\u2019s President and CEO. \u201cThese results support Bria-IMT\u2122 as a potential new therapeutic option for MBC patients with brain metastasis. We look forward to evaluating the brain metastasis patient subgroup in our ongoing pivotal Phase 3 study in metastatic breast cancer.\u201d<\/p>\n<p align=\"justify\">\u201cWe believe that the complete tumor resolution in this patient with brain metastasis, plus other cases of significant anti-cancer clinical responses in our Phase 2 MBC patients with brain metastasis, highlight the potential application of Bria-IMT\u2122 in treating similar MBC patients,\u201d commented Dr. Giuseppe Del Priore, BriaCell\u2019s Chief Medical Officer. \u201cThe protracted time on therapy, now one year, attests to the excellent tolerability of the Bria-IMT\u2122 regimen in combination with an immune checkpoint inhibitor which is being used in our pivotal Phase 3 study.\u201d<\/p>\n<p align=\"justify\"><strong>About BriaCell Therapeutics Corp.<\/strong><\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wXzs638d4VlvBs8lnxF6O_-8FFnuvPjy5TQIBV-euaAupGrodNZ96EP1giwj_orc_doxn7B0xOMyJls8WTqR0JoI8R-DD-rNk5OBWWRMYtU=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\"><strong>Safe Harbor<\/strong><\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell replicating positive data in its ongoing pivotal Phase 3 study; BriaCell\u2019s Bria-IMT\u2122 regimen bringing relief to cancer patients whose medical needs remain unmet; and the Bria-IMT\u2122 regimen becoming a therapeutic option for metastatic breast cancer patients, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3pRCG7NfxuS5oKhphGkO40hGiuzl8dWYqVuHK5NS-QsYYGAddY3qCiJzb0sFdDz9WwAbt3WB7EE366_Tsb7s-g==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>www.sedarplus.ca<\/strong><\/a> and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3pRCG7NfxuS5oKhphGkO4x_Ga-5aD6KiDCfQ8PhW1Cl4BeYFLw4OmRWT8YX-MYUpZn93tCLqvIFZkfDmmbo-1g==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\"><strong>Contact Information<\/strong><\/p>\n<p align=\"left\"><strong>Company Contact:<\/strong><br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ymtnojcsmZOFelkjeK27qzAfLKWpBHOR4sfmwW5QtKcOUefB6hb-afJX6UrGhBAph6aHP9sr2q-DRj-GjuxNn8EISqcNGH0L0dTptwrMIPk=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"info@briacell.com\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\"><strong>Media Relations:<\/strong><br \/>Jules Abraham<br \/>CORE IR<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=boaUGHaCXgE6Ol9wk__7hmtLjarQTBHjymukzA3xUYf33sG1PWyKJuhjgNDywaBedkPF8UKz77Anicp8pKFk12Bp8Br01FfBKk822le-Yb0=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"julesa@coreir.com\">julesa@coreir.com<\/a><\/p>\n<p align=\"left\"><strong>Investor Relations Contact:<\/strong><br \/>CORE IR<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zA5qi0p8tSLCIx7b69yss6E1GZ2W0TImrqdakKCz5jE2RRsNXwiWtcDIEyR5XSC8XrViEvUvTtc6iYHchiFfvjRO1J1OPp5rQRj43R987WA=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"investors@briacell.com\">investors@briacell.com<\/a><\/p>\n<p>Photos accompanying this announcement are available at<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wXzs638d4VlvBs8lnxF6O5LDkIORtrHdaUMamJl6VZwNQdEl3XNcO-GN1Q8SRgO_6XBx1Z9_TR6WUWaNV99ulkcEdzGPdtRlKqA7mTp7KnEr9cla4gGXPgb7GdnE7_A7XQ1wSMN58W3cLPTOE6XXrvcnHGLlaLCR4Ecr1DX7yvJzW7d2-SXCr3dvxaKCmJRzAo2cIXyJC2eHLtE8GqcS_UftxzuTyfi5ELbaVHdUPaHg-aLn5lw400uLjas8S_78ADZz2ABD_pYMQBuxZKTOJw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/0a328ad2-c48d-43bf-ae04-0b69da4d3f3f<\/a><\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wXzs638d4VlvBs8lnxF6O5LDkIORtrHdaUMamJl6VZwNQdEl3XNcO-GN1Q8SRgO_ufV0WmRkKvKey7DQjRxa1aYgvo4bSbe4sq670eD0rTVv5Cp4erTDn2M67HeyZAE_a4uR0R5v6slBpZZPC_t_xFBUSo-29TUPyiorgWoX34UI_GbwVa_q_47csDJ7Ei-d3KZMMdFc_Sso3_7CsdOP0Qi3-O0CkUcfhxEAz9Pk6fyr8gBv79pfY-njqGfj10OjhSZ6A8_4oMUsR6X81kZ1mA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/eea9560e-c63a-4001-a5b7-6a07caf3c91b<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWVhMTU3YmUtZWI5Ny00MDk0LTk3MGYtOWJiYTI3NTQ3NGFkLTExMDIyMjk=\/tiny\/BriaCell-Therapeutics-Corp-.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with \u201cEye-Bulging\u201d metastatic breast cancer Heavily pre-treated patient had failed 8 prior regimens including antibody-drug conjugate (ADC) therapy and continues to receive BriaCell treatment PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":85407,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/6fd3be2a-b6a2-4f35-a39c-dfd88259d9d0","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-85406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/85406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=85406"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/85406\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/85407"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=85406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=85406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=85406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}